FLT3-IN-13 (compound 20) is a highly effective inhibitor targeting both topoisomerase II and FLT3 proteins in leukemic cells. It exhibits potent activity against these targets, with IC50 values of 2.26 μM for both. Moreover, FLT3-IN-13 induces cell cycle arrest at the G2/M phase and promotes apoptosis. Notably, it displays considerable anticytotoxic activity, specifically against leukemia [1].

FLT3-IN-13 (compound 20) has strong antiproliferative activity against HL-60 with an IC 50 of 0.48 ± 0.08 μM [1]. FLT3-IN-13 arrests HL-60 cell cycle at G2/M phase (G1%: 24.76±1.00, S%: 21.26±1.72, G2%: 32.78±2.21, total apoptosis%: 21.36±2.73) [1]. FLT3-IN-13 induces apoptosis of HL-60 with early-apoptosis of 6.13±1.20% and late-apoptosis of 13.06±0.40% [1]. FLT3-IN-13 significantly upregulates P53, TNFα and caspase 3/7 proteins in the HL-60 cell line, and increases the Bax/Bcl-2 ratio [1].